8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Cedric Wiegand
8.8
- - Companion Diagnostics Development
- - 16 weeks January - May 2024
- - Pharmaceutical Company
Reviewed:
High-quality companion diagnostics development, delivered on time.
The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.
Harvey Sipes
5.8
- - Biostatistical Design
- - 6 weeks February - March 2024
- - Research Institution
Reviewed:
Biostatistical analysis lacked depth, missed key insights.
The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.
Alton Erdman
9.5
- - Gene Therapy Development
- - 12 weeks January - March 2023
- - Research Institution
Reviewed:
Innovative approach to gene therapy development, collaborative team.
The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.
Jody Emard MD
9.1
- - Pharmacovigilance Services
- - Ongoing
- - Pharmaceutical Company
Reviewed:
Highly effective pharmacovigilance services, ensured compliance.
The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.
Antonia Bergnaum
9.1
- - HTA Submission
- - 8 weeks February - March 2024
- - Biotech Company
Reviewed:
Comprehensive and well-executed HTA submission.
The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.
Marc Fisher
5.4
- - Process Development
- - 14 weeks June - September 2024
- - Biotech Company
Reviewed:
Process development project faced delays, communication issues.
The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.
Harvey King
8.7
- - Patient Recruitment
- - 8 weeks March - April 2023
- - Clinical Research Organization
Reviewed:
Highly effective patient recruitment strategies, project completed on time.
The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.
Joanna Kulas III
9.2
- - Data Visualization
- - 3 weeks December 2023
- - Pharmaceutical Company
Reviewed:
Highly effective data visualization, easy to interpret and impactful.
The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.
Ms. Opal Dooley
9
- - Clinical Protocol Design
- - 6 weeks April - May 2023
- - Pharmaceutical Company
Reviewed:
Comprehensive protocol design, very detailed and precise.
The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.
